Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EUTHROID-0.5 vs CYTOMEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Euthyroid-0.5 is a combination of liothyronine (T3) and levothyroxine (T4). T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors (TRα and TRβ) in the nucleus, regulating gene transcription involved in metabolism, growth, and development.
Liothyronine (T3) is a synthetic thyroid hormone that binds to thyroid hormone receptors in the nucleus, altering gene transcription and increasing basal metabolic rate, protein synthesis, and cardiovascular function.
Replacement therapy in hypothyroidism (primary, secondary, tertiary),Suppression of TSH in thyroid cancer (off-label),Treatment of euthyroid goiter (off-label)
Primary hypothyroidism (as replacement therapy),Thyroid-stimulating hormone (TSH) suppression in thyroid cancer,Myxedema coma (off-label),Nontoxic goiter (off-label)
Oral: 0.5 grains (30 mg) once daily, titrated to clinical response.
Initial adult dose 25 mcg orally once daily; titrate by 12.5-25 mcg increments every 1-2 weeks based on TSH and clinical response. Usual maintenance dose 50-100 mcg once daily. Maximum dose 100 mcg daily.
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal and hepatic function; clinically, steady-state is reached within 24-36 hours, and dosing interval adjustments may be needed in renal or hepatic impairment.
The terminal elimination half-life of liothyronine is approximately 1.0-2.5 days in euthyroid individuals, but may be prolonged in hypothyroidism (up to 3-4 days) and shortened in hyperthyroidism. Clinical context: This short half-life allows rapid dose titration and withdrawal for thyroid suppression tests.
Levothyroxine (T4) is deiodinated to liothyronine (T3) primarily by type 1 and type 2 deiodinases in liver, kidney, and other tissues. T3 and T4 are also metabolized via glucuronidation and sulfation. Hepatic enzymes: UGT1A1, UGT1A3, SULT1A1.
Primarily hepatic conjugation (glucuronidation and sulfation) and minor deiodination; not extensively metabolized by cytochrome P450.
Renal (approx. 20-40% as unchanged drug, primarily via glomerular filtration and tubular secretion); biliary/fecal (approx. 60-80% as metabolites and unchanged drug, with enterohepatic recirculation).
Liothyronine (T3) is primarily eliminated by hepatic metabolism (deiodination and conjugation). Approximately 50-60% of a dose is excreted in urine as metabolites, with less than 5% as unchanged drug. Fecal excretion accounts for about 20-30% via biliary elimination of conjugates.
Approximately 99% bound to serum proteins, primarily thyroxine-binding globulin (TBG), with lesser binding to transthyretin and albumin.
99.7% bound to plasma proteins, primarily thyroxine-binding globulin (TBG) (80%), transthyretin (10%), and albumin (10%).
Apparent volume of distribution is approximately 0.10-0.15 L/kg, indicating distribution primarily into extracellular fluid and highly protein-bound; small Vd reflects minimal tissue binding under steady-state conditions.
Volume of distribution is approximately 0.4-0.6 L/kg, indicating distribution into total body water. Clinical meaning: Vd is lower than for T4 due to higher protein binding; rapid distribution into tissues occurs.
Oral bioavailability: 100% (tablets), as EUTHROID-0.5 is a combination product with synthetic T4 (levothyroxine) and T3 (liothyronine); T4 absorption is ~80% (fasting, taken with water), while T3 is nearly completely absorbed; overall bioavailability considered complete when taken as directed.
Oral bioavailability is approximately 95% (range 90-100%) when taken on an empty stomach; food may slightly reduce absorption. Intravenous bioavailability is 100%.
No dose adjustment required for GFR >30 m L/min; for GFR <30 m L/min, consider reducing dose by 25-50% and monitor TSH.
No specific dose adjustment required for renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: avoid use or reduce dose by 50% and monitor TSH.
No specific dose adjustment required for hepatic impairment; monitor thyroid function closely.
Oral: 0.5-1 grain (30-60 mg) per 70 kg body weight once daily; for children <70 kg, use 0.5 grains (30 mg) once daily adjusted to TSH levels.
Initial 5 mcg orally once daily; increase by 5 mcg every 2-4 weeks based on thyroid function and clinical response. Maintenance: 25-50 mcg once daily. Weight-based: 1.6-2.6 mcg/kg/day.
Initiate at 0.5 grains (30 mg) orally once daily; titrate slowly with 0.5 grain increments every 4-6 weeks; monitor for tachyarrhythmias and osteoporosis.
Start with lower initial dose of 12.5-25 mcg orally once daily; titrate slowly (increase by 12.5 mcg every 2-4 weeks) due to increased sensitivity and higher risk of cardiac complications. Monitor TSH closely.
No FDA boxed warning.
Not approved for weight loss; serious cardiovascular toxicity or death may occur, especially when used with sympathomimetic amines.
Cardiovascular effects: angina, arrhythmias, heart failure. Thyrotoxicosis: excessive doses may cause symptoms of hyperthyroidism. Bone mineral density reduction with long-term overreplacement. Adrenal insufficiency: may precipitate crisis in untreated patients. Diabetes: insulin/oral hypoglycemic requirements may increase. Myxedema coma: rapid correction can be fatal.
Cardiovascular adverse effects (angina, arrhythmias, hypertension, myocardial infarction),Thyrotoxicosis from excessive dosing,May increase anticoagulant effect of warfarin,May reduce glycemic control in diabetes,Bone demineralization with prolonged use
Hypersensitivity to active ingredients or excipients. Untreated adrenal insufficiency. Thyrotoxicosis (hyperthyroidism). Acute myocardial infarction. Uncontrolled cardiovascular disease.
Untreated thyrotoxicosis,Acute myocardial infarction,Uncorrected adrenal insufficiency
Avoid taking with high-fiber foods, soy, or calcium supplements; separate by at least 4 hours.
High-fiber foods, walnuts, soybean flour, and cottonseed meal may reduce absorption. Avoid excessive intake of iodine-rich foods (e.g., kelp, seaweed). Maintain consistent dietary habits for stable drug absorption.
EUTHROID-0.5 contains levothyroxine. Thyroid hormones are not associated with major teratogenic risk. In the first trimester, maternal hypothyroidism (treated) is important to avoid, as untreated hypothyroidism is linked to congenital anomalies and neurodevelopmental deficits. No evidence of fetal harm from levothyroxine at therapeutic doses. Second and third trimester: transfers minimal amounts across placenta, but adequate maternal levels are essential for fetal neurodevelopment. Risk of fetal goiter if mother is overtreated (TSH suppression).
Pregnancy category A. Thyroid hormones do not readily cross the placenta in early pregnancy; insufficient maternal thyroid hormone may cause fetal neurodevelopmental deficits. In first trimester, untreated maternal hypothyroidism linked to miscarriage and fetal anomalies; replacement therapy reduces risk. Second and third trimesters: maternal hypothyroidism associated with preterm birth, low birth weight, and impaired cognitive development; adequate dosing is critical. No evidence of teratogenicity at therapeutic doses.
Levothyroxine is excreted into breast milk in minimal amounts, but no adverse effects in nursing infants have been reported. The milk-to-plasma (M/P) ratio is approximately 0.5 (range 0.4-0.6). Breastfeeding is considered safe while on levothyroxine therapy. Monitor infant thyroid function if high doses are used.
Liothyronine (T3) is excreted into human breast milk in low concentrations; M/P ratio not established. Exogenous T3 may suppress endogenous maternal thyroid function. Benefits of breastfeeding generally outweigh minimal risk; infant thyroid function should be monitored if mother requires high doses. Use with caution.
Pregnancy increases levothyroxine requirements in many women with hypothyroidism. Dose often increases by 30-50% starting at 4-6 weeks gestation. Monitor TSH and free T4 every 4-6 weeks and adjust dose accordingly to maintain euthyroid state. Postpartum, dose usually returns to prepregnancy levels.
Pregnancy increases T3 clearance and decreases serum T3 levels. Dose requirements may increase by 30–50% compared to prepregnancy baseline. Frequent monitoring of free T3 and TSH is required; adjust dose to maintain free T3 in the upper normal range and TSH within trimester-specific targets. Dose adjustments should be made in increments of 5–12.5 mcg daily. Postpartum, dose usually returns to prepregnancy levels.
Euthroid-0.5 contains liothyronine (T3). Monitor for signs of thyrotoxicosis due to rapid onset. T3 has a shorter half-life than levothyroxine; consider twice-daily dosing. Use with caution in elderly and patients with cardiac disease.
Initiate at low doses (5-12.5 mcg/day) in elderly or cardiac patients; increase gradually every 1-2 weeks. Monitor TSH, T3, and T4 levels; T3 therapy can cause rapid swings in thyroid hormone levels. Use with caution in adrenal insufficiency, coronary artery disease, or diabetes insipidus. May increase warfarin sensitivity; reduce anticoagulant dose. Discontinue 2-4 weeks before thyroid uptake scans.
Take exactly as prescribed, usually once daily.,Do not stop abruptly without consulting your doctor.,Report symptoms of hyperthyroidism: palpitations, tremor, anxiety, heat intolerance.,Store at room temperature away from moisture.
Take exactly as prescribed; do not change dose without consulting your doctor.,Take on an empty stomach, at least 30 minutes before food or other medications.,Notify your doctor if you experience chest pain, rapid heartbeat, nervousness, or excessive sweating.,Do not stop suddenly; abrupt withdrawal can cause hypothyroid symptoms.,Inform all healthcare providers you are taking this medication.,May increase sensitivity to blood thinners; report signs of bleeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EUTHROID-0.5 vs CYTOMEL, answered by our medical review team.
EUTHROID-0.5 is a Thyroid Hormone Replacement that works by Euthyroid-0.5 is a combination of liothyronine (T3) and levothyroxine (T4). T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors (TRα and TRβ) in the nucleus, regulating gene transcription involved in metabolism, growth, and development.. CYTOMEL is a Thyroid Hormone that works by Liothyronine (T3) is a synthetic thyroid hormone that binds to thyroid hormone receptors in the nucleus, altering gene transcription and increasing basal metabolic rate, protein synthesis, and cardiovascular function.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EUTHROID-0.5 and CYTOMEL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EUTHROID-0.5 is: Oral: 0.5 grains (30 mg) once daily, titrated to clinical response.. The standard adult dose of CYTOMEL is: Initial adult dose 25 mcg orally once daily; titrate by 12.5-25 mcg increments every 1-2 weeks based on TSH and clinical response. Usual maintenance dose 50-100 mcg once daily. Maximum dose 100 mcg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EUTHROID-0.5 and CYTOMEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EUTHROID-0.5 is classified as Category C. EUTHROID-0.5 contains levothyroxine. Thyroid hormones are not associated with major teratogenic risk. In the first trimester, maternal hypothyroidism (treated) is important to avoi. CYTOMEL is classified as Category C. Pregnancy category A. Thyroid hormones do not readily cross the placenta in early pregnancy; insufficient maternal thyroid hormone may cause fetal neurodevelopmental deficits. In f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.